Lung Infections

Biotech firm gets funding for cystic fibrosis foundation

Published in TB and Outbreaks Week, November 11th, 2003

Chiron Corporation (CHIR) announced funding for the establishment of the TOBI Foundation, an independent non-profit foundation dedicated to increasing access to TOBI (tobramycin solution for inhalation) for uninsured and underinsured people with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa, the most common type of bacterial lung infection in people with CF.

Officially launching during the 17th Annual North American Cystic Fibrosis Conference (NACFC) in Anaheim, California, the foundation will issue vouchers for TOBI to eligible families who have either no health insurance or prohibitively high copayments through their prescription drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry